Back to top
La crisis del coronavirus da impulso a Aurora Cannabis, pero sus cuentas siguen siendo un desastre

The coronavirus crisis has served the giants of the international cannabis market well. Or at least that's how it’s been for Aurora Cannabis, second in the industry in global level turnover. Founded in 2004 in Ontario, Canada, the company has recovered a good part of the market value that it lost in the last fourteen months. In May, its shares on the New York Stock Exchange increased by 158% after the financial results of its third fiscal quarter of 2020 (which covers the months of January to March of the current year in Canada, and which would be the first fiscal quarter in Spain) became known.

In those first months of 2020, Aurora Cannabis increased its sales by 16% compared to the previous quarter (October to December), from 65.14 million Canadian dollars to C$75.52 according to the company's accounts. This sales increase could have been the result of the coronavirus crisis. As detailed by CNBC at the end of March, the cannabis industry was reaching record sales by then: thousands of consumers were buying large quantities to stock up during confinement, and cannabis dispensaries were deemed an essential service in Canada and areas of the United States where recreational and / or medicinal cannabis are already regulated. This also benefitted Canopy Growth, the largest cannabis company: in 2019, it also saw its shares fall (by 70%) but has recovered by 25% due to the crisis.

 

 

But Aurora Cannabis’ results are not all that positive. In the same third quarter, the cost of products sold increased to C$43.6 million (compared with C$28.9 million in the previous period); gross profit dropped to C$27.4 million, little more than half of what was earned in the previous period (C$52.6 million). And here we can ask ourselves two questions: if sales have increased, why have profits halved? And why, if after looking at them it’s evident that Aurora Cannabis’ accounts aren’t too favourable, did the company experience a rise on the stock market this May?

The answer to the first question is easy: as explained by stock information website Market Watch, the demand for cannabis at cheaper prices has increased by 17% during these past months while the demand for cannabis at higher prices has dropped by 13%. The second question is more difficult to answer.

 

 

 

 

Just a few weeks before this recovery, Aurora Cannabis had had to reduce its number of shares on the New York Stock Exchange, where its price had dropped to a dollar per share versus $9 in early 2019. To avoid being de-listed from the New York Stock Exchange, Aurora Cannabis reduced its number of shares, giving each shareholder one for every twelve owned.

The burden on Aurora Cannabis’ accounts are purchases made in previous years. In 2018, one purchase was Med Releaf (one of its main rivals in Canada) for 3,200 million Canadian dollars - €2,093 million according to the exchange rate at that time.

Aurora Cannabis is the main sponsor of the Cannabis Europe platform in Madrid. In Europe it’s based in Berlin, and has become one of the main importers and distributors of medicinal cannabis on the continent, and also in Spain although the Spanish Agency for Medicines and Health Products has not yet been granted a licence to grow cannabis.

According to the latest data provided by the Canadian company, Aurora Cannabis’ global production has gone from around one million grams of cannabis produced between September and November 2016 to more than 40 million between September and November 2019.

It currently has 9,116 patents registered and has production facilities in Canada, Denmark, Uruguay and Germany, which adds up to a production capacity of more than 600,000 kilos of marijuana per year (although in the same report, Aurora Cannabis limits its annual production capacity to 150,000 kilos).

As appears in the report to investors, Aurora Cannabis sold 12,463 kilos of marijuana between July and September 2019. Each gram has a production cost of 0.85 Canadian dollars and 1.90 sales costs, reaching a profit margin of 58%. The selling price is around C$4.76 per gram as reported by Market Watch in February.

The cultivation of cannbis for personal consumption is an activity subject to legal restrictions that vary from state to state. We recommend consultation of the legislation in force in your country of residence to avoid participation in any illegal activity.

The purpose of this publication is purely informative, horizontal transfer of technical horticultural information.

Kannabia accept no responsibility for any illegal use made by third parties of information published here.

Comments

The cultivation of cannbis for self-consumption is an activity subject to legal restrictions that vary from state to state. We recommend consultation of the legislation in force in your country of residence to avoid participation in any illegal activity.

The purpose of this publication is purely informative, horizontal transfer of technical horticultural information.

Kannabia accept no responsibility for any illegal use made by third parties of information published here.